Foghorn Therapeutics Halts FHD-909 Expansion, Cuts ~40% Workforce

What Happened

• On Sept. 25, 2026, Foghorn Therapeutics announced it will not advance the Phase 1 trial of FHD-909 into the expansion phase following review of clinical data; further collaboration activities with Eli Lilly are not anticipated.
• On Sept. 30, 2026, Foghorn’s Board approved a strategic reprioritization and a workforce reduction of approximately 40% to focus resources on prioritized programs, with the company expecting to complete the reduction in Q4 2026 and retain about 65 full‑time employees.
• The company issued a press release on Oct. 1, 2026 disclosing these actions (attached as Exhibit 99.1 to the 8-K).

Key Details

• Workforce reduction: ~40% of current employees; expected post‑reduction headcount ≈ 65 full‑time employees.
• Timing: Reduction expected to be substantially completed in Q4 2026.
• Estimated charges: Aggregate charges of approximately $2.3 million, all expected to be cash expenditures (primarily one‑time severance and benefit costs) incurred in Q4 2026.
• Strategic focus: Company will prioritize its selective EP300 degrader, immunology & inflammation asset, selective CBP degrader, induced‑proximity platform, and other proprietary programs.

Why It Matters

• Near-term financial impact: The company expects about $2.3M in cash charges tied to severance/benefits in Q4 2026, which is a one‑time cost but will affect near‑term cash use and operating results.
• Strategic shift: Stopping FHD-909 expansion and pausing further Lilly collaboration signals a refocus of R&D resources onto a smaller set of internal programs — this may change Foghorn’s development timeline and risk profile for investors.
• Operational impact: A ~40% headcount reduction is material to operations and could affect execution speed; the company states the move is intended to concentrate resources where management sees greatest long‑term value.